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Introduction: Immunodeficient mice engrafted with human immune systems
support studies of human hematopoiesis and the immune response to human-
specific pathogens. A significant limitation of these humanized mouse models is,
however, a severely restricted ability of human B cells to undergo class switching
and produce antigen-specific IgG after infection or immunization.
Methods: In this study, we have characterized the development and function of
human B cells in NOD-scid IL2Rgnull (NSG) mice transgenically expressing human
stem cell factor (SCF), granulocyte macrophage colony-stimulating factor (GM-
CSF), and IL-3 (NSG-SGM3) following engraftment with human hematopoietic
stem cells, autologous fetal liver, and thymic tissues (bonemarrow, liver, thymus or
BLT model). The NSG-SGM3 BLT mice engraft rapidly with human immune cells
and develop T cells, B cells, and myeloid cells.
Results:A higher proportion of human B cells developing in NSG-SGM3BLTmice
had a mature/naive phenotype with a corresponding decrease in immature/
transitional human B cells as compared to NSGBLTmice. In addition, NSG-SGM3
BLT mice have higher basal levels of human IgM and IgG as compared with NSG
BLT mice. Moreover, dengue virus infection of NSG-SGM3 BLT mice generated
higher levels of antigen-specific IgM and IgG, a result not observed in NSG BLT
mice.
Conclusions: Our studies suggest that NSG-SGM3 BLT mice show improved
human B cell development and permit the generation of antigen-specific antibody
responses to viral infection.
Introduction
Immunodeficient mice engrafted with functional human
immune systems, termed ‘‘humanized mice,’’ are increas-
ingly being utilized to study human immunity as well as
infections, autoimmunity, allergies, organ transplantation,
vaccine development, and immune regulation [1, 2]. A key
factor for the successful generation of humanized mice is the
use of optimal mouse strains that enable the survival of
engrafted human cells and tissues. Immunodeficient scid,
Rag1null or Rag2null mice bearing mutations within the IL2
receptor gamma chain (IL2rg) gene support the robust
engraftment of human immune cells and tissues and the
development of functional human immune systems [3–6]. A
number of different strategies have been used to engraft
human immune systems in immunodeficient mice. These
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strategies include injection of human PBL (Hu-PBL-SCID
model) [7], injection of hematopoietic stem cells (HSC)
(Hu-SRC-SCID model) [3, 5], and implantation of human
fetal liver and thymus tissues in combination with injection
of autologous HSC (BLT or bone marrow/thymus/liver
model) [8, 9]. Each of these humanized mouse models has
distinct strengths and weaknesses, and selection of the
appropriate model is dependent on the specific experimental
question being addressed.
Current efforts to further enhance immune system
development and function in humanized mouse models
have focused on improving specific human immune cell
populations. One major limitation of the existing human-
ized mouse models is the severely limited ability of human B
cells in these mice to undergo class switching and affinity
maturation in response to pathogens or immunization with
protein antigens [10]. Antigen-specific antibody responses
are generated in these mice but they are largely of the IgM
isotype with very low IgG titers, which suggests inefficient
class switching [11, 12]. The restricted B cell responses in
humanized mice are an obstacle for studies of vaccine
development and infectious diseases where humoral
responses predominate. The limited ability of human B
cells to undergo class switching in humanized mice is
attributed to several factors including impaired T and B cell
maturation, lack of secondary lymphoid structures in the
peripheral lymphoid organs, poor reconstitution of myeloid
antigen-presenting cells (APCs), and insufficiency of human
cytokines [13–17]. Examples of approaches to improve
human B cell function include expression of HLA class II and
expression or injection of human cytokines that facilitate
hematopoiesis and lymphocyte differentiation. While these
approaches have enabled improvements in B cell function,
generation of high levels of antigen-specific IgG remains
problematic.
In this study, we evaluated human B cell development and
function in humanized NSG mice constitutively expressing
human stem cell factor (SCF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), and interleukin-3
(IL-3), also known as NSG-SGM3 mice. Previous studies
have shown that NSG-SGM3 mice have significantly
improved engraftment of human acute myeloid leukemia
(AML) cells as well as long-term pre-leukemic myeloid cell
cultures [18]. Moreover, NSG-SGM3 mice engrafted with
human CD34þ HSC have elevated levels of neutrophils [19]
and other granulocytes [20], myeloid dendritic cells (mDCs)
as well as CD4þ cells with a lineage skewing toward
regulatory T cells (Tregs) that were functionally and
phenotypically equivalent to human Tregs [21]. To test
the ability of NSG-SGM3 mice to support human B cell
development and function, these mice along with NSG mice
were transplanted with human fetal thymic and liver tissues
and autologous fetal liver derived CD34þ HSC to generate
BLT mice. Our results show that NSG-SGM3 BLTmice have
enhanced human B cell development, with higher levels of
mature naïve B cells and lower levels of immature
transitional and transitional B cells as compared with NSG
BLTmice. NSG-SGM3 BLTmice also had higher basal levels
of human IgM and IgG in the plasma as compared with
control NSG BLT mice. Finally, infection of NSG-SGM3
BLT mice with dengue virus stimulated the generation of
antigen-specific IgM and IgG responses at levels higher than
NSG BLT mice. Our results indicate that NSG-SGM3 mice
support enhanced development and maturation of human B
cells and will be a useful model to study human antigen-
specific B cell responses.
Materials and Methods
Mice
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD-scid IL2rgnull, NSG)
mice and NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,
KITLG)1Eav/MloySzJ (NSG-SGM3 mice) were obtained
from The Jackson Laboratory (Bar Harbor, ME). All animals
were housed in a specific pathogen free facility in micro-
isolator cages, given autoclaved food and maintained
on sulphamethoxazole-trimethoprim medicated water
(Goldline Laboratories, Ft Lauderdale, FL) and acidified
autoclaved water on alternate weeks. All experiments
were performed in accordance with the guidelines of
the Institutional Animal Care and Use Committee of the
University of Massachusetts Medical School and the
recommendations in the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal
Resources, National Research Council, National Academy
of Sciences, 1996).
Generation of BLT mice
Male and female NSG andNSG-SGM3mice at 6–10 weeks of
age were irradiated with 100 cGy and implanted with human
fetal thymus and liver fragments under the kidney capsule.
The fetal tissues (gestational age 16–20 weeks) were obtained
from Advanced Bioscience Resources (Alameda, CA). The
tissues were washed with RPMI supplemented with
penicillin G (100U/ml), streptomycin (100mg/ml), fungi-
zone (0.25mg/ml), and gentamycin (5mg/ml) and 1mm3
fragments of the fetal thymus and liver were implanted in the
renal subcapsular space. Mice were injected subcutaneously
with gentamycin (0.2mg) and cefazolin (0.83mg) post-
surgery. To obtain fetal HSC, fetal liver tissue was processed
as described previously [15], depleted of CD3þ T cells and a
cell suspension containing 1 to 2 105 CD34þ fetal liver
HSC was injected in the tail vein of mice between 4 and 6 h
after irradiation.
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Antibodies and flow cytometry
Fluorophore-linked primary antibodies (Supplemental
Table S1) used for analysis of hematopoietic cell engraftment
were purchased from BD Biosciences, Inc. (San Jose, CA),
eBiosciences (San Diego, CA), or BioLegend (San Diego, CA).
The following antibodies (clones) were used: mouse CD45
(30-F11), human CD45 (2D1), CD34 (581), CD3 (UCHT1),
CD20 (2H7), CD33 (WM53), CD4 (RPA-T4), CD8 (RPA-T8),
CD25 (MA-251and2A3),CD127(A019D5), Foxp3(236A/E7),
CD45RA (HI100), CD27 (M-T271), CD38 (HIT2), CD10
(HI10A), IgD (IAG-2), CD138 (MI15). Single cell suspensions
of spleen and bone marrow (recovered from one femur)
were prepared from mice and whole blood was collected
in heparin. Single cell suspensions of 0.5 to 1 106 cells or
50–100ml of heparinized whole blood were washed with FACS
buffer (PBS with 2% FBS and 0.02% sodium azide) and
incubated with rat anti-mouse CD16/CD32 (clone 2.4G2) for
5–7min at 48C to block Fc binding. Cells were then incubated
with antibodies for surface markers for 20min at 48C in the
dark. Stained samples were washed with FACS buffer and fixed
with 1% paraformaldehyde for cell suspensions or treated with
BD FACS lysing solution for whole blood to lyse red blood cells
(RBCs) and fix the samples. To detect human Tregs, blood
samples were stained for surface markers, lysed and fixed and
then incubated with eBioscience fixation/permeabilization
buffer for 60min. Cells were then stained with antibody against
human Foxp3 in eBioscience permeabilization buffer for
60min. At least 50,000 events were collected on LSRII flow
cytometer (BD Biosciences, Inc, San Jose CA) using the BD
FACSDIVA software. FlowJo software (Tree Star, Inc., Ashland,
OR) was used to analyze data.
Infections and ELISAs
Total human IgM and IgG concentrations were measured in
the plasma of mice by ELISA as per the manufacturer’s
instructions (Bethyl Laboratories, Inc., Montgomery, TX)
using an EMax Endpoint ELISA microplate reader (Molec-
ular Devices, Sunnyvale, CA). To measure dengue virus
specific antibody responses, mice were infected subcutane-
ously with approximately 106 plaque forming units (PFUs)
of dengue virus serotype-2 strain New Guinea C (DENV-2
NGC). The levels of dengue-specific IgM and IgG were
determined using inactivated dengue-2 antigen lysates in
ELISAs as described previously [12].
Statistical analyses
Statistical analyses were performed using GraphPad PRISM
software version 5 (GraphPad, San Diego, CA). An unpaired
t-test was performed to determine statistically significant
differences between mean values of each data set.
Results
NSG-SGM3 BLT mice show accelerated human cell
chimerism as compared to NSG BLT mice
BLT mice were generated on the NSG or NSG-SGM3
background and levels of human CD45þ hematopoietic cells
were examined in the blood at 6, 9, and 12 weeks post-
implantation and in spleen and bone marrow at week 12
(Fig. 1). Levels of human CD45þ hematopoietic cells were
significantly higher in the peripheral blood of NSG-SGM3
mice at 6, 9, and 12weeks as compared toNSGmice (Fig. 1A–
C). The levels of circulating human CD45þ cells in NSG BLT
mice continued to increase over time (13.7 1.6% at 6 weeks,
35.3 3.3% at 9 weeks, and 47.3 4.6% at 12 weeks). In
contrast, CD45þ cell levels in the blood of NSG-SGM3 BLT
mice reached maximal levels at 6 weeks and did not increase
significantly beyond that time point (52.7 2.2% at 6 weeks,
62.5 2.9% at 9 weeks, and 64.2 3.3% at 12 weeks). In the
spleen, the percentages and total numbers of human CD45þ
cells were similar between NSG and NSG-SGM3 mice at
12 weeks post-implantation (Fig. 1D and E). The percentages
and total numbers of humanCD45þ cells in the bonemarrow
were similar between NSG and NSG-SGM3 mice at 12 weeks
post-implantation (Fig. 1F and G). Together these results
indicated that NSG-SGM3 mice support the rapid engraft-
ment of human hematopoietic cells.
NSG-SGM3 BLT mice support human T cell
development
A significant advantage of the BLT model is the efficient
development of human T cells on autologous human thymic
tissues. Human CD3þ T cell development in NSG-SGM3
BLT and NSG BLT mice was monitored in the blood at 6, 9,
and 12 weeks post-implantation and in spleen and bone
marrow at week 12 (Fig. 2). Levels of human T cells were
significantly lower in the blood of NSG-SGM3 mice
compared to NSG mice and the differences were significant
over time (Fig. 2A–C). T cell engraftment improved with
the age of mice in both groups. NSG-SGM3 mice had
lower percentages of human T cells in the spleen compared
to NSG mice at 12 weeks (Fig. 2D), but total numbers of
T cells were similar (Fig. 2E). Human T cell levels were low in
the bone marrow of both groups of mice, with significantly
higher percentages (Fig. 2F) detected in NSG-SGM3 mice
compared to NSG mice and similar numbers for each group
(Fig. 2G).
NSG-SGM3 BLT mice support human B cell
development
Human CD20þ B cell development in NSG-SGM3 BLT and
NSG BLT mice was monitored in the blood at 6, 9, and
S. Jangalwe et al. Human B cell development in NSG-SGM3 mice
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12 weeks post-implantation and in spleen and bone marrow
at week 12 (Fig. 3). Levels of human B cells were significantly
lower in the blood of NSG-SGM3 mice at week 6 compared
to NSG mice but the levels were comparable at weeks 9 and
12 (Fig. 3A–C). NSG-SGM3 and NSG mice had similar
percentages and total numbers of human B cells in the spleen
(Fig. 3D and E) and bone marrow (Fig. 3F and G) at
12 weeks.
Figure 1. Human CD45þ cell engraftment kinetics in the peripheral blood, spleen, and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. NSG
and NSG-SGM3 mice were irradiated with 100 cGy and implanted with 1mm3 of human fetal thymus and liver in the renal subcapsular space. All mice
were injected intravenously with 1 105 CD34þ hematopoietic stem cells (HSC) derived from autologous fetal liver. The peripheral blood of the recipient
NSG BLT and NSG-SGM3 BLTmicewas screened for total human hematopoietic CD45þ cell engraftment at the 6-week (A), 9-week (B), and 12-week (C)
post-transplantation time points. The spleen (D and E) and bone marrow (F and G) of NSG BLT and NSG-SGM3 BLT mice were screened for total human
CD45þ cell engraftment 12 weeks after transplantation of human fetal tissues. Engraftment results are represented as a percentage of total cells or as
total numbers in the spleen (D and E) and in the bone marrow (F and G). p< 0.05; p< 0.01; p< 0.0001. Each symbol indicates an individual BLT
mouse. The results for peripheral blood are from four independent experiments and for spleen and bonemarroware from two independent experiments.
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NSG-SGM3 BLT mice support enhanced myeloid
cell development compared to NSG BLT mice
Previous studies have shown that NSG-SGM3 mice
engrafted with human HSC have significantly improved
myeloid cell development [18–21]. Human CD33þmyeloid
cell development in NSG-SGM3 BLT and NSG BLT mice
was monitored in the blood at 6, 9, and 12 weeks post-
implantation and in spleen and bone marrow at week 12
(Fig. 4). At all time points tested significantly higher levels of
human CD33þ cells were detected in the blood of NSG-
SGM3 BLTmice as compared to NSGBLTmice (Fig. 4A–C).
In the spleen, the percentages and total numbers of human
CD33þ cells were significantly higher in NSG-SGM3 mice at
Figure 2. Human CD3þ T cell engraftment kinetics in the peripheral blood, spleen, and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. The
peripheral blood of the NSG BLT and NSG-SGM3 BLT mice was screened for total human CD3þ T cell engraftment at 6-week (A), 9-week (B), and 12-
week (C) post-transplantation of human fetal tissues. The spleen (D and E) and bone marrow (F and G) of NSG BLT and NSG-SGM3 BLT mice were
screened for human CD3þ T cell engraftment 12weeks after transplantation of human fetal tissues. Engraftment results are represented as a percentage
of total human CD45þ cells or as total numbers in the spleen (D and E) and in the bonemarrow (F and G). Each symbol indicates an individual BLTmouse.
The results for peripheral blood are from four independent experiments and for spleen and bone marrow are from two independent experiments.
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12 weeks post-implantation compared to NSG mice
(Fig. 4D and E). The percentages and total numbers of
human CD45þ cells in the bone marrow were similar
between NSG and NSG-SGM3mice at 12 weeks (Fig. 4F and
G). Together, these data show that NSG-SGM3 BLT mice
show a heightened development of human myeloid
development as has been found in HSC-engrafted NSG-
SGM3 mice [21].
NSG-SGM3 BLT mice show improved engraftment
of CD4þ regulatory T cells as compared to NSG
BLT mice
NSG-SGM3 mice engrafted with human HSC have previously
been shown to have enhanced development of CD4þ human
Tregs [21].We characterized T-cell subsets inNSG-SGM3BLT
mice, by comparing CD4þ to CD8þ T cell ratios, Treg levels
Figure 3. Human CD20þ B cell engraftment kinetics in the peripheral blood, spleen, and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. The
peripheral blood of the NSG BLT and NSG-SGM3 BLT mice was screened for total human CD20þ B cell engraftment at 6-week (A), 9-week (B), and 12-
week (C) post-transplantation of human fetal tissues. The spleen (D and E) and bone marrow (F and G) of NSG BLT and NSG-SGM3 BLT mice were
screened for human CD20þ B cell engraftment 12 weeks after transplantation of human fetal tissues. Engraftment results are represented as a
percentage of total humanCD45þ cells or as total numbers in the spleen (D and E) and in the bonemarrow (F andG). p< 0.05; p< 0.01; p< 0.001;
p< 0.0001. Each symbol indicates an individual BLT mouse. The results for peripheral blood are from four independent experiments and for spleen
and bone marrow are from two independent experiments.
Human B cell development in NSG-SGM3 mice S. Jangalwe et al.
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and T cell phenotype in the blood of both groups of mice
at 12 weeks post-tissue implantation (Fig. 5). The CD4þ to
CD8þ ratio was approximately 5:1 in both strains of
mice (Fig. 5A). Significantly higher levels of human
CD4þCD25þCD127loFoxp3þ T regulatory cells were detected
in the blood of NSG-SGM3 mice compared to NSG mice
(Fig. 5B).Analysis ofCD45RAexpression levels byhumanCD4
andCD8Tcells showeda lowerproportionofT cells expressing
CD45RA in the blood of NSG-SGM3 mice compared to NSG
mice (Fig. 5CandD).These data indicate thatNSG-SGM3BLT
mice have higher levels of CD4þ regulatory T cells, and lower
levels of naïve CD4þ and CD8þ T cells.
Figure 4. Human CD33þ myeloid cell engraftment kinetics in the peripheral blood, spleen, and bone marrow of NSG BLT mice and NSG-SGM3 BLT
mice. The peripheral blood of the NSG BLT and NSG-SGM3 BLT mice was screened for total human CD33þmyeloid cell engraftment at 6-week (A), 9-
week (B), and 12-week (C) post-transplantation of human fetal tissues. The spleen (D and E) and bonemarrow (F and G) of NSG BLT and NSG-SGM3 BLT
mice were screened for human CD33þ myeloid cell engraftment 12 weeks after transplantation of human fetal tissues. Engraftment results are
represented as a percentage of total human CD45þ cells or as total numbers in the spleen (D and E) and in the bone marrow (F and G). In (B), data points
shown for NSG-SGM3BLT are a combination of 8 and 9week time points. p< 0.05; p< 0.01; p< 0.001; p< 0.0001. Each symbol indicates an
individual BLT mouse. The results for peripheral blood are from four independent experiments and for spleen and bone marrow are from two
independent experiments.
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NSG-SGM3 BLT mice develop higher levels of
mature naïve B cells compared to NSG BLT mice
Previous studies have described a predominance of imma-
ture B cells in humanizedmice [11, 14, 15]. To evaluate B cell
development in NSG-SGM3 BLT mice, we examined the
phenotype of B cells in the periphery (Fig. 6). B cells were
categorized into five groups based on their phenotypic
markers; immature/transitional B cells (CD27CD10þ),
transitional B cells (CD27CD10CD38þ), mature naïve B
cells (CD27CD10IgDþ), memory B cells (CD27þCD10),
and plasma cells (CD138þ) (for gating strategy see
Supplemental Fig. S1). Immature/transitional B cells were
present at comparable levels in the peripheral blood of NSG-
SGM3 and NSG mice (Fig. 6A). NSG-SGM3 mice had lower
levels of immature/transitional B cells in the spleen (Fig. 6B)
and bone marrow (Fig. 6C). Transitional human B cells were
significantly lower in blood (Fig. 6D) and spleen (Fig. 6E) of
NSG-SGM3 mice compared to NSG mice and levels were
similar in the bone marrow (Fig. 6F). Mature/naïve B cells
were significantly higher in the blood (Fig. 6G), spleen
(Fig. 6H) and bone marrow (Fig. 6I) of NSG-SGM3 mice
compared to control NSG mice. Healthy human adults have
between 60–70% mature naïve B cells in the peripheral
blood [22]. Memory B cells were present at significantly
higher levels in the blood of NSG-SGM3 mice compared to
NSG mice (Fig. 6J) and similar in spleen and bone marrow
(Fig. 6K and L). Healthy human adults are reported to have
10–30% memory B cells circulating in blood [22]. Plasma
cells were present at very low levels in both groups of mice in
all tissues (Fig. 6M–O). Together these data indicate that
NSG-SGM3 BLT mice have lower levels of immature and
transitional B cells and higher levels of mature naïve B cells
relative to NSG BLT mice, suggesting that the NSG-SGM3
BLT mice have improved human B cell maturation.
NSG-SGM3 BLT mice show an improved ability to
generate IgG antibodies
A major limitation of humanized mice is their reduced
ability to generate human IgG responses. The enhanced
human B cell maturation observed in the NSG-SGM3 BLT
mouse model (Fig. 6) suggested that these mice may have an
increased ability to undergo Ig class switching. The basal
levels of human IgM and IgG in the plasma of resting BLT
mice were therefore evaluated at 12 weeks post-tissue
implant. NSG-SGM3 mice had 5.6-fold higher levels of
human IgM compared to NSG mice (Fig. 7A). Human IgG
levels were 4.5-fold higher in NSG-SGM3 mice compared to
NSGmice (Fig. 7B). Next we infected the mice with DENV-2
(dengue virus serotype-2) and assessed the generation of
DENV-2 specific antibodies by sandwich ELISA 4 weeks
post-infection. We previously demonstrated the generation
of IgM responses to the inactivated lysates of dengue antigen
and the DENV-2 E (envelope) protein in NSG BLT mice but
Figure 5. Characterization of human CD3þ T cells in the peripheral blood of NSG BLT and NSG-SGM3 BLT mice at 12 week-post transplantation. The
ratio of human CD4:CD8 T cells gated onCD3þ T cells is shown in (A). The proportion of CD25þCD127lowFoxp3þ regulatory T cells (Treg) gated on CD4þ
T cells is shown in (B). The percentages of CD4þ and CD8þ T cells expressing naïve T cell marker CD45RA are shown in (C) and (D), respectively.
p< 0.001; p< 0.0001. Each symbol indicates an individual BLT mouse. The results for peripheral blood are from two independent experiments.
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limited antigen-specific IgG responses [23]. NSG-SGM3
BLT mice infected with DENV-2 had significantly higher
levels of DENV-2 specific IgM (Fig. 7C) and increased levels
of DENV-2 specific IgG (Fig. 7D). These data indicate that
transgenic expression of SCF, GM-CSF, and IL-3 generates
higher levels of total human IgM and IgG suggesting
improved class switching and induces improved viral
antigen-specific antibody responses.
Figure 6. Characterization of humanCD20þ B cells in the peripheral blood, spleen, and bonemarrow of NSG BLT and NSG-SGM3 BLTmice at 12weeks
post-transplantation. Human B cells were divided into ﬁve categories and expressed as a percentage of total human CD20þ B cells: CD20þCD27CD10þ
immature transitional B cells in blood (A), spleen (B), bone marrow (C); CD20þCD27CD10CD38þ transitional B cells in blood (D), spleen (E), bone
marrow (F); CD20þCD27CD10IgDþmature naïve B cells in blood (G), spleen (H), bone marrow (I); CD20þCD27þCD10memory B cells in blood (J),
spleen (K), bone marrow (L) and CD20þCD138þ plasma cells in blood (M), spleen (N), bone marrow (O). p< 0.05; p< 0.01; p< 0.001;
p< 0.0001. Each symbol indicates an individual BLT mouse. The results for peripheral blood are from three independent experiments and for spleen
and bone marrow are from two independent experiments.
S. Jangalwe et al. Human B cell development in NSG-SGM3 mice
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Discussion
The BLT model enables the generation of humanized mice
having a complete human immune system, including the
development of both conventional and regulatory HLA-
restricted T cells. Although B cells develop in BLT mice, the
circulating antibody levels are significantly lower compared
to adult humans. Moreover, the generation of antigen-
specific antibody responses in BLT mice, specifically IgG
responses, are weak, limiting their use in studying humoral
responses to pathogens and testing candidate vaccines [10].
Two studies have demonstrated that the immunoglobulin
gene repertoires of human B cells in humanized (HSC-
engrafted) mice are similar to those of normal human
peripheral B cells suggesting that humanized mice have the
genetic potential to mount broad and high affinity antibody
responses to diverse pathogens [24, 25]. The poor antigen-
specific antibody responses are unlikely to be attributed to a
genetic defect in the immunoglobulin repertoire. Studies
have suggested that the contributing factors are defects in T
and B cell maturation, disorganized secondary lymphoid
structures, and an absence of human cytokines [13–17].
Mature B cells that encounter their cognate antigen in
lymphoid follicles and receive T cell help enter a germinal
center where they undergo the processes of class switching,
that generates different antibody isotypes, and somatic
hypermutation, that diversifies their antibody reper-
toire [26]. Activated B cells can then differentiate into
plasmocytes and become antibody-secreting plasma cells
or become long-lived memory B cells. Human B cells
develop in NSG-BLT mice and generate human immuno-
globulins although at lower levels than in adult
humans [15]. Human B cells in humanized mice have
been shown to generate antigen-specific antibody re-
sponses to human immunodeficiency virus 1 (HIV-1)
[11, 27], West Nile virus [11], dengue virus [23], and
Epstein–Barr virus (EBV) [28]. These antibody responses
are predominantly of the IgM isotype with very little to no
IgG responses. A few studies have demonstrated antigen-
specific IgG responses in a small subset of mice infected
with HIV-1 [29, 30], albeit at low titers. The inability to
efficiently generate antibody response to most antigens has
necessitated the development of humanized mouse models
with improved class-switching.
Figure 7. Evaluation of total antibody titers and dengue virus speciﬁc antibody responses in NSG BLT and NSG-SGM3 BLT mice. Mice were bled at
12 weeks post-implantation of human tissues and total human IgM (A) and human IgG (B) levels (ng/ml) were determined in the plasma of thesemice by
ELISA. Mice were infected with DENV-2 and plasma samples were tested to determine DENV-2 speciﬁc IgM (C) and IgG (D) by sandwich ELISA. Each
symbol indicates an individual BLT mouse. The results from two independent experiments.
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The expression of human transgenes and inactivation of
specific mouse genes has improved humoral responses in
some models. Transgenic expression of human signal
regulatory protein alpha (SIRP alpha) in BALB/c-Rag2/
IL2rgnull mice that were injected with human HSC signifi-
cantly elevated the total levels of human IgG in theplasma, but
could not elicit a strong IgG response to the protein antigen
ovalbumin (OVA) [31]. However, transgenic expression of
HLA-DR4 in NOD-Rag1/ IL2rgnull mice engrafted with
HLA-DR4þ HSC elicited an IgG response to tetanus toxoid
vaccine as well as class switching to IgA, IgE, and all subtypes
of IgG [32]. In addition HLA-DR4 expression in NOD
Shi-scid IL2rgnull mice induced an anti-OVA IgG re-
sponse [33]. Expression of specific human cytokines has
also improved the engraftment of human hematopoietic cells
and enhanced the development and function of human
immune cells, including B cells [16]. Administration of the
recombinant human cytokine BAFF (B cell activating factor,
also called BLyS) toNOD-Rag1/Prf1/mice injectedwith
human peripheral blood lymphocytes (PBL) improved the
engraftment ofB cells, elevated serum immunoglobulin levels,
and generated an antibody response to thymus-independent
antigens in pneumovax vaccine [34]. Hydrodynamic injec-
tionof humanGM-CSF and IL-4 inHSC-engraftedNSGmice
allowed the induction of tetanus toxoid specific IgG as well as
neutralizing antibodies against H5N1 influenza virus upon
immunization [35]. While the approaches described above
have improved human B cell functionality in humanized
mice, further advancements are necessary to make these
models applicable to study human B cell immunity.
In this study, we have shown that NSG-SGM3 BLT mice
that transgenically express human SCF (also called c-kit
ligand or Steel factor), GM-CSF and IL-3 show heightened
human B cell engraftment consistent with the important role
of these human hematopoietic growth factors in hemato-
poiesis as well as in proliferation and survival of HSC in
vitro [36]. Moreover, NSG-SGM3 mice show accelerated
kinetics of human immune system development as
compared to NSG-BLT mice (Fig. 1). In our initial studies
that have followed survival of NSG-BLT and NSG-SGM3
BLT mice, we have noted earlier onset of GVHD-symptoms
in the SGM3mice, generally occurring 3 weeks prior to NSG
mice (data not shown). Given these accelerated kinetics,
NSG-SGM3 mice should be used in experiments beginning
at 9 weeks post-engraftment. Three studies have described
HSC-engrafted NSG mice transgenically expressing mem-
brane bound SCF [20, 37, 38]. In one study, transgenic
expression of membrane bound SCF circumvented the need
for irradiation and permitted high levels of engraftment of
human CD45þ cells in HSC engrafted NSG mice [37].
Another study reported these mice to have an improved
human myeloid cell compartment, specifically cells of the
granulocytic lineage [38]. A recent study showed that the
human myeloid cells in the SCF NSG mice migrated to
the renal tissue to become resident dendritic cells and some
of these mice could be used as a source of human bone
marrow-derived macrophages [20]. GM-CSF and IL-3 are
important for the development and function of myeloid
cells. Human IL-3/GM-CSF knock-in mice engrafted with
human HSC were shown to have improved myeloid cell
reconstitution in the lung and the engrafted human alveolar
macrophages mounted an innate immune response to
influenza virus showing that the myeloid cells were
functionally responsive [39]. NSG-SGM3 mice engrafted
with human HSC (the Hu-SRC-SCID model) have been
described previously [21]. These mice were shown to have
elevated myeloid cell frequencies, specifically myeloid DCs,
and CD4þ Foxp3þ regulatory T cells. NSG-SGM3 BLT mice
have a similar increase in myeloid cell levels (Fig. 4) and
Tregs (Fig. 5B).
Interestingly, NSG-SGM3 BLT mice had significantly
higher frequencies of mature naïve B cells and proportion-
ately reduced frequencies of immature and transitional B
cells compared to control NSG BLT mice (Fig. 6). Immature
B cells develop from the lymphoid progenitors in the bone
marrow by passing through the pro-B and pre-B cell stages.
These immature B cells expressing surface IgM (sIgM) exit
the bone marrow and enter into the periphery. The early
bone marrow emigrants are called immature transitional B
cells and they express the markers CD10 and CD38 [40]. In
the periphery, they develop into transitional B cells that can
gain access to lymphoid follicles in the spleen and become
more sensitive to T cell help. Upon receiving appropriate
cytokine signals and positive signals through the B-cell
receptor, they become mature B cells that repopulate the
periphery [41]. Successful differentiation from the transi-
tional to mature B cell stage is governed by the cytokine
BAFF [42]. BAFF is a member of the TNF (tumor necrosis
factor) family and is secreted mainly by myeloid cells such as
neutrophils, monocytes, macrophages, and dendritic
cells [43]. BAFF is also shown to be produced by activated
T cells to some extent [44]. We propose two explanations for
improved B cell maturation observed in NSG-SGM3 BLT
mice. Firstly, the increased frequencies of activated T cells
characterized as CD45RA (Fig. 5C and D) could facilitate B
cell maturation in NSG-SGM3 mice. Recently, Lang et al.
demonstrated a requirement of T cells for human B cell
maturation in BALB/c-Rag2/ IL2rgnullmice engrafted with
CD34þ HSC [45]. The study showed that adoptive transfer
of autologous T cells elevated mature B cell frequencies,
whereas T cell depletion diminished mature B cell levels. T
cell activation, characterized by the expression of CD45RO,
HLA-DR and CD49d, correlated with B cell maturation
suggesting T cell activation might be important for B cell
maturation. We did not find increased numbers of T cells in
NSG-SGM3 BLT mice relative to NSG BLT mice (Fig. 2).
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However, the increased frequencies of CD45RA activated T
cells (Fig. 5C and D) in NSG-SGM3 BLTmice could possibly
explain the improved B cell maturation in these mice.
Secondly, the well engrafted human myeloid cell compart-
ment in the NSG-SGM3 mice (Fig. 4) could secrete
increasing amounts of human BAFF that binds the BAFF-
R on transitional B cells rescuing them fromdeath and easing
them into the mature B cell stage. Also consistent with its
role of a ‘‘survival cytokine,’’ BAFF would bind BAFF-R on
mature B cells mediating their longevity and thus elevating
the mature B cell frequencies. Currently, we are evaluating
the role of BAFF in driving B cell maturation in NSG-SGM3
BLT mice.
Since improved B cell maturation contributes to enhanced
B cell functionality in terms of antigen-specific antibody
responses, we tested the hypothesis that improved B cell
maturation in NSG-SGM3 BLT mice would generate
antigen-specific antibody responses. Previously, we demon-
strated that NSG BLT mice can elicit DENV-2 antigen-
specific antibody responses which are predominantly of the
IgM class [23]. NSG-SGM3 BLT mice elicited significantly
stronger IgM as well as IgG responses to inactivated DENV-2
lysates relative to NSG BLTmice. We propose that improved
B cell maturation in these mice contributes to the enhanced
levels of human immunoglobulins and antigen-specific
antibody responses. The histology sections of spleens of NSG
and NSG-SGM3 BLT mice upon dengue infection showed
similarly disorganized architecture ruling out the formation
of organized secondary lymphoid structures in NSG-SGM3
mice (data not shown). However, we cannot rule out other
mechanisms for enhanced antibody responses in these mice.
To summarize, transgenic expression of SCF, GM-CSF,
and IL-3 in NSG BLT mice resulted in improved human
myeloid cell reconstitution, enhanced B cell maturation, and
antigen-specific antibody responses to dengue virus infec-
tion. Thus, NSG-SGM3 BLTmice prove to be a useful tool to
study antibody responses to viral infections. Further
improvements in B cell development, such as the develop-
ment of secondary lymphoid structures to support class
switching, engraftment of human follicular dendritic cells,
and enhanced B and T cell maturation, are necessary to
achieve strong humoral responses. In the future, supple-
mentation of humanized mice with human ‘‘survival
cytokines’’ like BAFF and IL-7 might be a positive step in
resolving the issue of impaired B cell development and
function.
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